Table 3.

Prognostic value of Oncotype DX in all subjects (n=144,357)

	# of patients	# of death	Hazard ratio (95% CI)	C-index (95% CI)
All subjects
Low risk (RS 0–10)	33,731	803	1.00 (ref.)	0.574 (0.565–0.583)
Intermediate risk (RS 11–25)	89,871	2,166	0.95 (0.88–1.03)
High risk (RS >25)	20,755	1,201	2.26 (2.06–2.47)
Per 10 unit increase			1.32 (1.29–1.35)	0.577 (0.566–0.588)
Node negative
Low risk (RS 0–10)	27,795	634	1.00 (ref.)	0.578 (0.567–0.589)
Intermediate risk (RS 11–25)	73,951	1,609	0.90 (0.82–0.98)
High risk (RS >25)	17,582	928	2.13 (1.93–2.36)
Per 10 unit increase			1.31 (1.28–1.35)	0.573 (0.560–0.585)
Node positive
Low risk (RS 0–10)	5,936	169	1.00 (ref.)	0.581 (0.562–0.599)
Intermediate risk (RS 11–25)	15,920	557	1.15 (0.97–1.36)
High risk (RS >25)	3,173	273	2.94 (2.43–3.56)
Per 10 unit increase			1.38 (1.31–1.44)	0.593 (0.571–0.615)
Non-Hispanic White
Low risk (RS 0–10)	28,534	679	1.00 (ref.)	0.578 (0.568–0.588)
Intermediate risk (RS 11–25)	76,244	1,844	0.96 (0.88–1.04)
High risk (RS >25)	16,905	1029	2.39 (2.17–2.64)
Per 10 unit increase			1.33 (1.30–1.37)	0.581 (0.570–0.593)
African American
Low risk (RS 0–10)	2,420	92	1.00 (ref.)	0.545 (0.517–0.573)
Intermediate risk (RS 11–25)	6,519	228	0.89 (0.70–1.13)
High risk (RS >25)	2,147	127	1.44 (1.10–1.88)
Per 10 unit increase			1.18 (1.11–1.26)	0.535 (0.502–0.569)
Hispanic
Low risk (RS 0–10)	1,475	18	1.00 (ref.)	0.519 (0.465–0.573)
Intermediate risk (RS 11–25)	3,811	64	1.23 (0.73–2.07)
High risk (RS >25)	865	18	1.41 (0.73–2.70)
Per 10 unit increase			1.21 (1.05–1.40)	0.542 (0.477–0.608)
Asian American
Low risk (RS 0–10)	2,982	14	1.00 (ref.)	0.617 (0.545–0.689)
Intermediate risk (RS 11–25)	3,297	30	0.78 (0.41–1.47)
High risk (RS >25)	838	27	2.57 (1.35–4.90)
Per 10 unit increase			1.52 (1.30–1.78)	0.586 (0.496–0.676)